IL2RA and non-Hodgkin lymphoma: Notable solid tumors exhibiting heightened sCD25 levels encompass lung adenocarcinoma, esophageal cancer, and head and neck cancer.33In addition, hematological malignancies displaying elevated sCD25 concentrations include select cases of acute leukemias and non-Hodgkin's lymphoma.34The current understanding identifies the cell surface interleukin-2 receptor α-chain (IL-2Rα, CD25) as a robust prognostic indicator for unfavorable outcomes in patients diagnosed with AML.35The treatment of tumors targeting IL2Rα has seen the development of two distinct approaches.